A23V2400/533

NOVEL BIFIDOBACTERIUM BACTERIA AND COMPOSITION INCLUDING NOVEL BIFIDOBACTERIUM BACTERIA

Provide are beneficial bacteria that can be beneficially applied across a wide range of age groups and a composition containing the same. Bifidobacterium longum subspecies longum NITE BP-02568 and/or Bifidobacterium longum subspecies longum NITE BP-02569; and Bifidobacterium longum subspecies longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

METHODS FOR IMPROVING GASTROINTESTINAL BARRIER FUNCTION AND INHIBITING GROWTH OF ENTERIC PATHOGENIC BACTERIA
20230201280 · 2023-06-29 ·

Disclosed herein are methods for improving gastrointestinal barrier function, alleviating a gastrointestinal barrier dysfunction-associated disorder, and inhibiting growth of enteric pathogenic bacteria using a composition containing Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115, which are deposited at the China General Microbiological Culture Collection Center (CGMCC) respectively under accession numbers CGMCC 21225, CGMCC 15212, and CGMCC 21840. A number ratio of Lactobacillus rhamnosus MP108, Bifidobacterium longum subsp. infantis BLI-02, and Bifidobacterium animalis subsp. lactis BB-115 ranges from 1:0.2:0.67 to 1:9:9.

NOVEL LACTIC ACID BACTERIA AND USE THEREOF
20220370523 · 2022-11-24 ·

The present invention relates to the novel lactic acid bacteria Lactobacillus mucosae and Bifidobacterium longum, and specifically, to a composition comprising the novel lactic acid bacteria, the composition enabling the inhibition of the expression of the p16 protein, which is an aging factor, and the inhibition of inflammatory factors, thereby being useful in preventing and treating memory impairment, learning disabilities or mental disorders, and in preventing and treating inflammatory diseases.

MATERNAL MILK POWDER CONTAINING PROBIOTICS AND PREBIOTICS AND PREPARATION METHOD THEREOF

A maternal milk powder and a preparation method thereof. Every 100 g of the maternal milk powder comprises: (0.1-10)×10.sup.8 CFU of probiotics, 1-10 g of FOS; wherein, probiotics comprise Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium animalis, and Bifidobacterium bifidum with a CFU ratio of 20-40:20-40:1-10:10-20:10-20:1-10. The maternal milk powder can effectively inhibit the proliferation of harmful bacteria in the intestinal tract of pregnant women, promote the health of intestinal microecology, improve immunity, relieve postpartum depression, etc. by adding six kinds of safe, stable and efficient probiotics and FOS.

Use of microbial communities for human and animal health

The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

STRAINS OF LACTOBACILLUS AND BIFIDOBACTERIA FOR THE MAINTENANCE OF A LONG-LASTING HOMEOSTASIS CONDITION IN A HUMAN BODY
20170326186 · 2017-11-16 ·

Selected strains of bacteria belonging to the genus Lactobacillus and Bifidobacteria being able to maintain a long-lasting homeostasis condition in a human body are described. Furthermore, a composition is also described, including a food composition, a supplement product, a composition for a medical device or a pharmaceutical composition for use in the treatment of a long-lasting homeostasis condition in a human body; or for use in the treatment of renal failure, preferably acute or chronic; or for use in reducing uremic toxins, preferably of bacterial origin, such as indole and/or cresol.

SYMBIOTIC SUPPLEMENT FORMULATION FOR IMPROVING INTESTINAL MICROBIOTA

Described is a symbiotic formulation for the oral consumption of probiotics and prebiotics with an aqueous extract of roselle, with vitamins and proteins for humans. The invention belongs to the field of nutrition and has been developed to help to maintain a healthy digestive system by restoring and/or improving the intestinal microbiota. The purpose of the antioxidants and the synergic effect of the symbiotic formulation is to reduce the inflammatory process so as to facilitate the absorption of nutrients and thus improve the good nutritional state of people. An oral symbiotic formulation based on an aqueous roselle extract with encapsulated probiotics and which can contribute to the consumption of antioxidants of natural origin, the ingestion of proteins and micronutrients for re-establishing or improving the state of the intestinal microbiota, as well as the nutritional state of adults and older people, has not been found in the prior art.

COMPOSITION FOR MAINTENANCE AND/OR IMPROVEMENT OF MEMORY/LEARNING ABILITY, AND FOOD, MEDICINE AND FEED EACH CONTAINING SAID COMPOSITION

A medicine, a food or a drink and feed which are effective for preventing and/or improving decline, occurring with age (senescence), in memory and learning ability are provided. A novel microorganism having the effect of preventing and/or improving decline, occurring with age (senescence,) in memory and learning ability is provided. More specifically, the microorganism is characterized by being a microorganism belonging to Lactobacillus, Bifidobacterium, Streptococcus, Leuconostoc or Pediococcus, more specifically a microorganism belonging to any of Lactobacillus acidophilus, Lactobacillus gasseri, Lactobacillus gallinarum, Lactobacillus johnsonii, Lactobacillus delbrueckii subsp. delbrueckii, Bifidobacterium catenulatum, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Streptococcus thermophiles, Leuconostoc mesenteroides subsp. dextranicum, Leuconostoc lactis, Pediococcus acidilactici and Pediococcus pentosaceus.

Bifidobacterium longum

The multiple embodiments described herein comprise the genome of a probiotic Bifidobacterium longum bifidobacteria strain and genes encoded by the genome. Various novel Bifidobacterium longum are described.

Nutritional supplement system

A multi-part nutritional supplement system supplies nutrients to a user at advantageous locations in the digestive tract. One type of dosage unit is formulated to release vitamin B12 in the stomach and intestines of the upper GI tract, advantageously in an amount that is greater than or at multiple levels of the DV (Daily Value) of vitamin B12.